There is no single best treatment for Parkinson's disease. Levodopa is the most effective medicine for slowness, stiffness and tremor, and most people end up taking it. Other medicines, exercise, physiotherapy and, for a minority, deep brain stimulation surgery are added or chosen according to age, symptoms and side effects. No treatment cures the disease or is proven to stop it progressing.
Is there one best treatment for Parkinson's disease?
No. The NHS states there is no cure for Parkinson's disease and that treatment aims to reduce the main symptoms and maintain quality of life. Which treatment is best depends on the person: their age, how much the symptoms limit daily life, how they respond to medicines and which side effects they can tolerate.
The building blocks are the same everywhere. Medicines that replace or protect dopamine treat the movement symptoms. Physiotherapy, occupational therapy and speech and language therapy keep people mobile, independent and able to swallow safely. Deep brain stimulation surgery helps a small group of people with troublesome fluctuations or tremor. The NHS notes that people in the early stages may not need any treatment at all, only regular check-ups.
The Cleveland Clinic describes Parkinson's as a progressive movement disorder in which dopamine-producing brain cells slowly stop working, with symptoms most often starting around age 60. Treatment therefore changes over the years. A plan that works in year one, often a single medicine or exercise alone, usually needs additions and dose changes later as the disease progresses and as levodopa's effect becomes shorter.
The practical answer to "what is best" is a neurologist, ideally one who sees many movement disorder patients, reviewing the plan regularly. You can find one through our neurologist listings.
How does levodopa work and when is it started?
Levodopa is a chemical that nerve cells in the brain convert into dopamine, the messenger that Parkinson's destroys. The NHS explains that it is combined with carbidopa or benserazide, which stop it being broken down before it reaches the brain and reduce side effects. Treatment starts at a very small dose, which is gradually increased.
The NHS says that at first levodopa "can cause a dramatic improvement in the symptoms". Common side effects are nausea and vomiting, tiredness and dizziness. Over the years its effects become less long-lasting, so doses may need to rise. Two long-term problems follow: dyskinesias (involuntary jerky movements) and "on-off" effects, where a person switches rapidly between moving well and being stuck.
Dose matters. A 2023 review by di Biase and colleagues in the Journal of Clinical Medicine cites the ELLDOPA trial, in which dyskinesia occurred in 16% of patients on 600 mg a day over 8 months versus 3% on 150 mg a day. The same review states that levodopa "still remains the most effective pharmacological treatment" for Parkinson's.
There is no fixed age or stage at which levodopa must start. The NHS lists MAO-B inhibitors as an alternative for early Parkinson's, and dopamine agonists as a milder substitute. Younger people are sometimes started on these first because they face more years of levodopa exposure, but the deciding factor is how much the symptoms limit daily life.
Which other Parkinson's medicines exist and when is each used?
Five other drug classes are used alongside or instead of levodopa. The table below summarises what the NHS and the Cleveland Clinic say about each.
| Medicine class | Examples | When it is used | Main side effects (NHS) |
|---|---|---|---|
| Dopamine agonists | Pramipexole, ropinirole, rotigotine patch | Milder substitute for dopamine; often early disease or with levodopa | Nausea, sleepiness, dizziness, hallucinations, impulse control problems, sudden sleep |
| MAO-B inhibitors | Selegiline, rasagiline | Alternative to levodopa in early disease; add-on later | Nausea, headache, abdominal pain, blood pressure changes |
| COMT inhibitors | Entacapone | Later stages, to extend levodopa's effect when it wears off | Nausea, diarrhoea, abdominal pain |
| Amantadine | Amantadine | To reduce levodopa-induced dyskinesia (Cleveland Clinic) | Not listed on the pages opened |
| Anticholinergics | Trihexyphenidyl | May reduce tremor (Cleveland Clinic) | Not listed on the pages opened |
| Apomorphine | Injection or pump | Rescue for sudden "off" periods, or continuous infusion | As for dopamine agonists |
The NHS says MAO-B inhibitors have small effects compared with levodopa and are generally well tolerated. Dopamine agonists need caution in older people because they can cause hallucinations and confusion.
For people with severe on-off fluctuations, the NHS describes co-careldopa gel pumped continuously into the gut through a tube. The Cleveland Clinic lists foslevodopa and apomorphine delivered continuously under the skin by a pump for persistent on and off periods. These are specialist options, not first-line treatment.
What are dyskinesia and impulse control problems, and how are they managed?
Dyskinesia and impulse control disorders are the two side effects that most often change a Parkinson's treatment plan. Dyskinesias are uncontrollable, jerky movements linked to long-term levodopa. The 2023 Journal of Clinical Medicine review reports that in a 5-year trial of initial levodopa, 45% developed dyskinesias, rising to 77.8% at 10 years; a community study found 11% with under 5 years of levodopa, 32% at 6 to 9 years and 89% after 10 years. Risk factors include younger age, higher dose and longer duration. Management, per the review, means reducing or spreading levodopa doses, adding amantadine, continuous delivery by pump, or deep brain stimulation.
Impulse control disorders are repetitive, compulsive pleasure-seeking behaviours: pathological gambling, hypersexuality, compulsive shopping and binge eating. Gatto and Aldinio's 2019 review in Frontiers in Neurology cites the DOMINION study of 3,090 patients, which found an overall prevalence of 17.1%, with dopamine agonist use linked to 2 to 3.5 times higher odds. In a French cohort the 5-year cumulative incidence was about 46%.
The first step when these behaviours appear is to reduce or stop the dopamine agonist, under supervision, because the review warns that withdrawal can worsen movement symptoms and the behaviours may persist for at least 12 weeks.
Tell the neurologist the same week if a person on Parkinson's medicine starts gambling, shopping or eating compulsively, or shows a new sexual preoccupation. The NHS says the person may not realise the change themselves, so family members should watch for it.
Who is a candidate for deep brain stimulation?
Deep brain stimulation (DBS) is for people whose Parkinson's still responds to levodopa but who have motor complications that medicines cannot control. The NHS describes it as a pulse generator implanted in the chest wall connected to fine wires placed in specific brain areas, available at specialist neuroscience centres; surgery does not cure the disease but "can ease the symptoms for some people".
Umemura and colleagues, in a 2016 review in Neurologia medico-chirurgica, set out the usual criteria. The best candidate has fluctuations and dyskinesia from dopaminergic medicines, or disabling tremor despite optimal drug treatment. An initial good response to levodopa indicates a correct diagnosis; atypical parkinsonism does not respond to surgery. The candidate should have no dementia or active psychiatric illness. Ideally the patient is under 70.
A 2020 paper by Artusi and colleagues in the Journal of Clinical Medicine notes that the older CAPSIT-PD criteria required at least five years of disease and at least a 33% improvement in the UPDRS motor score on a levodopa challenge. The EARLYSTIM trial enrolled people with a diagnosis of four years or more and fluctuations for four years or less, with a mean disease duration of 7.3 years in the surgical group.
Benefits and risks are both real. Umemura's review reports that subthalamic DBS improves off-medication motor scores by 52% and reduces dyskinesia by 69%, with 30-day mortality of 0.4%, symptomatic brain haemorrhage in 2.0% and infection in 2.0% of pooled cases.
Does exercise or physiotherapy actually help Parkinson's?
Yes. A 2023 Cochrane review by Ernst and colleagues pooled 156 randomised trials with 7,939 participants, mostly with mild to moderate disease. Most types of exercise improved the severity of motor signs and quality of life, with "little evidence of differences between these interventions". The authors suggest the type of exercise may matter less than exercising at all.
| Exercise type | Effect on motor signs (SMD vs no exercise) | Certainty of evidence |
|---|---|---|
| Dance | -0.77 | High |
| Aqua-based (water) | -0.58 | Low |
| Gait, balance and functional training | -0.55 | Low |
| Multi-domain programmes | -0.52 | Low |
| Strength or resistance | -0.52 | Very low |
| Mind-body (tai chi, yoga) | -0.49 | Low |
| Endurance (walking, cycling) | -0.48 | Low |
For quality of life, aqua-based training had the only moderate-certainty result, a large effect. Safety evidence was very uncertain; falls and pain were the most commonly reported problems, so supervised programmes make sense for people with balance trouble.
The NHS describes physiotherapy as movement and exercise to relieve muscle stiffness and joint pain, aiming for easier movement, better walking and flexibility, and improved fitness. Occupational therapy solves practical problems such as dressing. Speech and language therapy treats swallowing and speech difficulties, which the NHS says many people develop. A physiotherapist who treats neurological conditions can build a programme that mixes balance, strength and endurance work.
What newer treatments are backed by trials?
Three newer approaches have trial or review evidence behind them; the rest remain experimental.
Earlier surgery. The EARLYSTIM trial, discussed by Artusi and colleagues in 2020, offered subthalamic DBS to people with four or more years of disease and recent motor complications. Only 0.8% of the cohort was later re-diagnosed with a different condition, and the authors report that stimulation improved off-medication freezing of gait, present in 52% at baseline. People with very good quality-of-life scores before surgery gained little, so earlier does not mean everyone.
Continuous drug delivery. The 2023 Journal of Clinical Medicine review describes continuous levodopa or apomorphine, including levodopa-carbidopa gel delivered into the small intestine, as an option for all types of dyskinesia, while noting that the gel did not fully abolish dyskinesias. The NHS says these pump treatments are only available for severe on-off fluctuations or involuntary movements. Foslevodopa-foscarbidopa, which the Cleveland Clinic describes as delivered continuously under the skin by a pump, avoids the gut tube.
Adaptive stimulation. The Parkinson's Foundation notes that an adaptive DBS feature, which adjusts stimulation to brain signals, received FDA approval in 2025. Long-term outcome data were not on the pages we opened.
We did not find a Cochrane, NHS or NIH source describing focused ultrasound outcomes, so we have left it out. Stem cell therapy, gene therapy and supplements sold as neuroprotective have no cited trial evidence on any page we reviewed; a neurologist can say which clinical trials are recruiting in India.
What does Parkinson's treatment cost in India and where should you be treated?
The only Indian cost data we could cite comes from a 2022 study of 200 patients at a North Indian tertiary hospital movement disorder clinic, published by Ola and colleagues in the Annals of Indian Academy of Neurology. The median direct cost of care was ₹27,315 a year (2018 rupees), with medicines making up about 68.5% of it. Costs rose with disease stage: a median of about ₹11,350 at Hoehn and Yahr stage 1, ₹20,325 at stage 2, ₹50,238 at stage 3 and ₹71,108 at stage 4. Direct costs took about 11.4% of median yearly income, and patients in stages 3 and 4 spent more than a fifth of their income on drugs.
Only 5% of those patients had health insurance, and 10.5% quit jobs or lost income because of the disease. Six patients had DBS, at a median hospital cost of ₹5,25,000; most were government employees who were reimbursed. The authors describe treatment as out of reach for many and call for universal health insurance. The study notes that generic or free government drug schemes could lower the estimates; ask at government medical colleges and Ayushman Bharat empanelled hospitals.
In practice: see a neurologist for diagnosis and a yearly plan, ask about a physiotherapy programme early, keep a diary of on and off periods, and discuss DBS referral if fluctuations or tremor stop responding to medicine. This guide is general information from the sources listed below, not medical advice; a registered doctor makes decisions with you.
